ADARx Pharmaceuticals, Inc. Common Stock (ADRX) — Cash Flow-to-Debt Ratio
ADARx Pharmaceuticals, Inc. Common Stock (ADRX) has a Cash Flow-to-Debt Ratio of -0.04x as of June 2026, meaning its operating cash flow of $-27.19 Million could theoretically repay 0% of its total liabilities ($707.38 Million) in one year. Check ADARx Pharmaceuticals, Inc. Common Stock cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
ADARx Pharmaceuticals, Inc. Common Stock Cash Flow-to-Debt Ratio (2024–2025)
Historical debt coverage capacity for ADARx Pharmaceuticals, Inc. Common Stock across 2 annual periods. See ADRX equity to assets ratio to measure how much of total assets are equity-financed.
Annual Cash Flow-to-Debt Ratio for ADARx Pharmaceuticals, Inc. Common Stock (2024–2025)
Year-by-year debt coverage analysis for ADARx Pharmaceuticals, Inc. Common Stock. For the full cash flow conversion analysis, see ADARx Pharmaceuticals, Inc. Common Stock (ADRX) cash flow conversion.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.37x | $262.29 Million | $709.91 Million | ▲ +382.0% |
| 2024 | -0.13x | $-48.56 Million | $370.60 Million | — |